Pancreatic ductal adenocarcinoma (PDAC) is a very serious type of cancer with a low survival rate. Doctors use medicines called chemotherapy to treat it, but it doesn't always work well for everyone. This study aims to use patient-derived organoids (PDOs), which are tiny 3D models made from a patient's tumor cells, to help predict how well the chemotherapy will work for each person. By studying these organoids, researchers hope to find out which chemotherapy is best for each patient without using a trial-and-error method.

• The study lasts two years, from February 2026 to February 2028.
• No extra risks or treatments are involved, as it uses leftover tissue from surgeries.
• Participants won't benefit directly, but the study could help future patients.

To join, you must be between 18-75 years old and have PDAC, with planned chemotherapy treatment. The study is conducted at six hospitals in China. It includes regular follow-ups and assessments. All participants need to sign a consent form, and the study respects privacy and ethical guidelines.